Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13360)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jun 7, 2021 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol 2021; 27(21): 2727-2757 [PMID: 34135551 DOI: 10.3748/wjg.v27.i21.2727] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i21/2727.htm |
| Number | Citing Articles |
| 1 |
Lucie Hozáková, Barbora Vokatá, Tomáš Ruml, Pavel Ulbrich. Targeting the Virus Capsid as a Tool to Fight RNA Viruses. Viruses 2022; 14(2): 174 doi: 10.3390/v14020174
|
| 2 |
Jie Lin, Shiyao Jiang, Xiangyu Chen, Min Zhu, Haifeng Zhang. The significance of detecting HBV pgRNA and HBcrAg in HBV patients treated with NAs. Medicine 2024; 103(14): e37752 doi: 10.1097/MD.0000000000037752
|
| 3 |
Xiaojiao Li, Yusi Liu, Hanxin Yao, Meng Wang, Lei Gao, Jinfeng Lou, John Mao, Wenqiang Wu, Yixin Zhou, Yanan Tang, Wenhao Yan, Yanbin Hu, Charles Ding, Shuhui Chen, Junqi Niu, Yanhua Ding. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial. Antimicrobial Agents and Chemotherapy 2022; 66(5) doi: 10.1128/aac.00094-22
|
| 4 |
Caleb A. Starr, Smita Nair, Sheng-Yuan Huang, Michael F. Hagan, Stephen C. Jacobson, Adam Zlotnick. Engineering Metastability into a Virus-like Particle to Enable Triggered Dissociation. Journal of the American Chemical Society 2023; 145(4): 2322 doi: 10.1021/jacs.2c10937
|
| 5 |
Huihui Yang, Weiwei Yao, Jinfei Yang. Overview of the development of HBV small molecule inhibitors. European Journal of Medicinal Chemistry 2023; 249: 115128 doi: 10.1016/j.ejmech.2023.115128
|
| 6 |
Gerardo B. Figueroa, Simmone D'souza, Higor S. Pereira, Gunjan Vasudeva, Sara B. Figueroa, Zachary E. Robinson, Maulik D. Badmalia, Vanessa Meier‐Stephenson, Jennifer A. Corcoran, Guido van Marle, Yi Ni, Stephan Urban, Carla S. Coffin, Trushar R. Patel. Development of a single‐domain antibody to target a G‐quadruplex located on the hepatitis B virus covalently closed circular DNA genome. Journal of Medical Virology 2024; 96(6) doi: 10.1002/jmv.29692
|
| 7 |
Dariusz Zakrzewicz, Joachim Geyer. Interactions of Na+/taurocholate cotransporting polypeptide with host cellular proteins upon hepatitis B and D virus infection: novel potential targets for antiviral therapy. Biological Chemistry 2023; 404(7): 673 doi: 10.1515/hsz-2022-0345
|
| 8 |
Xixi Fan, Fei Wang, Hongxiao Song, Fengchao Xu, Xiaolu Li, Qi Wei, Bingxin Lei, Zhongnan Wang, Yue Wang, Guangyun Tan. Baicalin inhibits the replication of the hepatitis B virus by targeting TRIM25. Journal of Traditional and Complementary Medicine 2023; 13(6): 561 doi: 10.1016/j.jtcme.2023.05.009
|
| 9 |
Jieyu Dai, Tao Chen, Ryan Meng, Ferran Jardi, Stephanie Kourula, Ly Pham, Sandra De Jonghe, Ann De Smedt, Anna‐Lena Frisk, Jianxun Xie. Species differences in small intestinal exposure‐related epithelial vacuolation in rats and dogs treated with a heteroaryldihydropyrimidine molecule. Journal of Applied Toxicology 2024; 44(3): 400 doi: 10.1002/jat.4550
|
| 10 |
Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang. Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies. World Journal of Gastroenterology 2024; 30(10): 1295-1312 doi: 10.3748/wjg.v30.i10.1295
Abstract(379) |
Core Tip(375) |
Full Article(HTML)(1853)
|
Full Article with Cover (PDF)-1506K(111)
|
Full Article (Word)-897K(0)
|
Audio-407K(3)
|
Peer-Review Report-310K(39)
|
Answering Reviewers-316K(39)
|
Full Article (PDF)-1251K(144)
|
Full Article (XML)-349K(40)
|
Times Cited (1)
|
Total Visits (3965)
|
Open
|
| 11 |
Leda Bassit, Franck Amblard, Dharmeshkumar Patel, Nicolas Biteau, Zhe Chen, Mahesh Kasthuri, Shaoman Zhou, Raymond F. Schinazi. The premise of capsid assembly modulators towards eliminating HBV persistence. Expert Opinion on Drug Discovery 2023; 18(9): 1031 doi: 10.1080/17460441.2023.2239701
|
| 12 |
Cornelis J.M. Melief, Anna-Sophia Wiekmeijer, Esmé T.I. van der Gracht. Cancer Vaccines as Immunotherapy of Cancer. 2022; : 97 doi: 10.1016/B978-0-12-823901-8.00013-3
|
| 13 |
Jordan J Feld, Eric Lawitz, Tuan Nguyen, Jacob Lalezari, Tarek Hassanein, Paul Martin, Steven-Huy Han, Douglas Dieterich, Jeanne-Marie Giard, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L Conery, Nathalie Adda. EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B. Antiviral Therapy 2022; 27(6): 135965352211278 doi: 10.1177/13596535221127848
|
| 14 |
Bo Feng, Jia-Rui Zheng. Importance of quantitative HBsAg detection in whole course management of patients with chronic hepatitis B. World Chinese Journal of Digestology 2022; 30(15): 655 doi: 10.11569/wcjd.v30.i15.655
|
| 15 |
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery. Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients. Clinical and Molecular Hepatology 2024; 30(3): 375 doi: 10.3350/cmh.2023.0535
|
| 16 |
Maria Guadalupe Martinez, Emmanuel Combe, Aurore Inchauspe, Philippe Emmanuel Mangeot, Elodie Delberghe, Fleur Chapus, Gregory Neveu, Antoine Alam, Kara Carter, Barbara Testoni, Fabien Zoulim, Jianming Hu, Monica J. Roth. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants. mBio 2022; 13(2) doi: 10.1128/mbio.02888-21
|
| 17 |
Iman Ibrahim Salama, Samia M Sami, Somaia I Salama, Ghada A Abdel-Latif, Fatma A Shaaban, Walaa A Fouad, Aida M Abdelmohsen, Hala M Raslan. Current and novel modalities for management of chronic hepatitis B infection. World Journal of Hepatology 2023; 15(5): 585-608 doi: 10.4254/wjh.v15.i5.585
Abstract(572) |
Core Tip(493) |
Full Article(HTML)(3138)
|
Full Article with Cover (PDF)-3003K(161)
|
Full Article (Word)-511K(33)
|
Audio-567K(3)
|
Peer-Review Report-323K(49)
|
Answering Reviewers-310K(49)
|
Full Article (PDF)-1702K(217)
|
Full Article (XML)-450K(43)
|
Times Cited (3)
|
Total Visits (6740)
|
Open
|
| 18 |
Tamás Vermes, Mark Kielpinski, Thomas Henkel, Miquel A. Pericàs, Esther Alza, Angelica Corcuera, Helmut Buschmann, Thomas Goldner, Andreas Urban. An automated microfluidic platform for the screening and characterization of novel hepatitis B virus capsid assembly modulators. Analytical Methods 2022; 14(2): 135 doi: 10.1039/D1AY01227D
|
| 19 |
Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang. The progress of molecules and strategies for the treatment of HBV infection. Frontiers in Cellular and Infection Microbiology 2023; 13 doi: 10.3389/fcimb.2023.1128807
|
| 20 |
Jie-Li Hu, Ai-Long Huang. Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics. Virologica Sinica 2024; 39(1): 9 doi: 10.1016/j.virs.2023.12.005
|
| 21 |
Siyu Li, Na Li, Shanru Yang, Haiyan Deng, Yanguo Li, Yixuan Wang, Jiaqiang Yang, Jiaxin Lv, Lan Dong, Guansen Yu, Xin Hou, Geng Wang. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. International Immunopharmacology 2022; 109: 108842 doi: 10.1016/j.intimp.2022.108842
|
| 22 |
Hyun Young Woo, Jeong Heo, Won Young Tak, Heon Ju Lee, Woo Jin Chung, Jung Gil Park, Soo Young Park, Young Joo Park, Yu Rim Lee, Jae Seok Hwang, Young Oh Kweon, Jee-Fu Huang. Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial. PLOS ONE 2022; 17(7): e0270716 doi: 10.1371/journal.pone.0270716
|
| 23 |
Mariana Daniela Ignat, Alexia Anastasia Stefania Balta, Raisa Eloise Barbu, Miruna Luminita Draganescu, Luiza Nechita, Doina Carina Voinescu, Aurel Nechita, Ioana Anca Stefanopol, Camelia Busila, Liliana Baroiu. Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future. Journal of Clinical Medicine 2024; 13(7): 2055 doi: 10.3390/jcm13072055
|
| 24 |
Yi Zhang, Minli Guo, Xinyue Zhang, Nan Zhang, Ping Zhu, Hao Wang. Multiple optimizations of recombinant plasmid for improving expression of Hepatitis B core antigen in Escherichia coli. Protein Expression and Purification 2022; 198: 106127 doi: 10.1016/j.pep.2022.106127
|
| 25 |
Yanbin Hu, Fei Sun, Qiang Yuan, Jinhua Du, Lihong Hu, Zhengxian Gu, Qiong Zhou, Xiaoting Du, Shibo He, Ya Sun, Qian Wang, Lirong Fan, Lina Wang, Shaohua Qin, Shuhui Chen, Jian Li, Wenqiang Wu, John Mao, Yixin Zhou, Qiaoyun Zhou, George Zhang, Charles Z. Ding. Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection. Bioorganic & Medicinal Chemistry Letters 2022; 75: 128977 doi: 10.1016/j.bmcl.2022.128977
|
| 26 |
Lili Zhou, Shaohuai Xia, Yaoyao Liu, Qiang Ji, Lifeng Li, Xuan Gao, Xiaodi Guo, Xin Yi, Feng Chen. A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma. Lipids in Health and Disease 2023; 22(1) doi: 10.1186/s12944-023-01780-9
|
| 27 |
Percy A. Knolle, Li-Rung Huang, Anna Kosinska, Dirk Wohlleber, Ulrike Protzer. Improving Therapeutic Vaccination against Hepatitis B—Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection. Vaccines 2021; 9(11): 1333 doi: 10.3390/vaccines9111333
|
| 28 |
Iman Waheed Khan, Mati Ullah Dad Ullah, Mina Choudhry, Mukarram Jamat Ali, Muhammad Ashar Ali, Sam L. K. Lam, Pir Ahmad Shah, Satinder Pal Kaur, Daryl T. Y. Lau. Novel Therapies of Hepatitis B and D. Microorganisms 2021; 9(12): 2607 doi: 10.3390/microorganisms9122607
|
| 29 |
Siyi Xu, Jinlan Huang, Zhen Xun, Shiqi Li, Ya Fu, Ni Lin, Wennan Wu, Tianbin Chen, Can Liu, Qishui Ou, Jing Han.
IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2
In Vitro
. Microbiology Spectrum 2022; 10(6) doi: 10.1128/spectrum.01557-22
|
| 30 |
Saket Jhajharia, Fritz Lai, Heng Boon Low, Kiren Purushotorman, Bhuvaneshwari D/O Shunmuganathan, Conrad En Zuo Chan, Rachel Hammond, Hans-Jürgen Netter, Qingfeng Chen, Seng Gee Lim, Paul A. MacAry. Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus. npj Vaccines 2022; 7(1) doi: 10.1038/s41541-022-00516-7
|